NASDAQ:HBIO - Harvard Bioscience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.40 -0.08 (-3.23 %)
(As of 05/21/2019 04:00 PM ET)
Previous Close$2.48
Today's Range$2.40 - $2.49
52-Week Range$2.26 - $6.70
Volume217,508 shs
Average Volume145,713 shs
Market Capitalization$90.45 million
P/E Ratio16.07
Dividend YieldN/A
Beta1.33
Harvard Bioscience, Inc. provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion and temperature controllers, and microincubation and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions under the DSI and Buxco brands. It markets its products in approximately 100 countries through sales organizations, Websites, catalogs, and distributors to research scientists at pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Receive HBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
Current SymbolNASDAQ:HBIO
CUSIP41690610
Phone508-893-8999

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120.77 million
Cash Flow$0.3822 per share
Book Value$2.13 per share

Profitability

Net Income$-2,920,000.00

Miscellaneous

Employees519
Market Cap$90.45 million
Next Earnings Date7/25/2019 (Estimated)
OptionableOptionable

Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) announced its quarterly earnings results on Thursday, May, 2nd. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.01. The medical instruments supplier had revenue of $28.23 million for the quarter, compared to the consensus estimate of $28.50 million. Harvard Bioscience had a positive return on equity of 5.95% and a negative net margin of 1.45%. View Harvard Bioscience's Earnings History.

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Harvard Bioscience.

What guidance has Harvard Bioscience issued on next quarter's earnings?

Harvard Bioscience issued an update on its FY 2019 earnings guidance on Thursday, February, 28th. The company provided earnings per share (EPS) guidance of $0.21-0.23 for the period, compared to the Thomson Reuters consensus estimate of $0.26. The company issued revenue guidance of $124-126.5 million, compared to the consensus revenue estimate of $126.18 million.

What price target have analysts set for HBIO?

2 Wall Street analysts have issued 1-year price objectives for Harvard Bioscience's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Harvard Bioscience's stock price to reach $11.00 in the next year. This suggests a possible upside of 358.3% from the stock's current price. View Analyst Price Targets for Harvard Bioscience.

What is the consensus analysts' recommendation for Harvard Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harvard Bioscience.

Has Harvard Bioscience been receiving favorable news coverage?

Press coverage about HBIO stock has trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Harvard Bioscience earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Harvard Bioscience's key competitors?

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include LightPath Technologies (LPTH), NVIDIA (NVDA), Micron Technology (MU), General Electric (GE), Johnson & Johnson (JNJ), Celgene (CELG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA) and Anthera Pharmaceuticals (ANTH).

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the folowing people:
  • Mr. Jeffrey A. Duchemin, CEO, Pres & Director (Age 53)
  • Ms. Kamalam Unninayar, Chief Financial Officer (Age 51)
  • Mr. Russell J. Sylvia, VP of Global HR
  • Mr. Corey Manchester, VP & Corp. Controller

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.91%), Dimensional Fund Advisors LP (5.44%), Acadian Asset Management LLC (2.05%), Renaissance Technologies LLC (1.65%), Foundry Partners LLC (1.39%) and Cadence Capital Management LLC (1.38%). Company insiders that own Harvard Bioscience stock include Earl R Lewis, George Uveges, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Institutional Ownership Trends for Harvard Bioscience.

Which institutional investors are selling Harvard Bioscience stock?

HBIO stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC, Adirondack Research & Management Inc., ARS Investment Partners LLC, BlackRock Inc., Renaissance Technologies LLC, Morgan Stanley, Oxford Asset Management LLP and Acadian Asset Management LLC. Company insiders that have sold Harvard Bioscience company stock in the last year include Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.

Which institutional investors are buying Harvard Bioscience stock?

HBIO stock was bought by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, Monarch Partners Asset Management LLC, Falcon Point Capital LLC, Wedge Capital Management L L P NC, Dalton Greiner Hartman Maher & Co., Assenagon Asset Management S.A., Alambic Investment Management L.P. and Marshall Wace LLP. Company insiders that have bought Harvard Bioscience stock in the last two years include Earl R Lewis, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.

How do I buy shares of Harvard Bioscience?

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $2.40.

How big of a company is Harvard Bioscience?

Harvard Bioscience has a market capitalization of $90.45 million and generates $120.77 million in revenue each year. The medical instruments supplier earns $-2,920,000.00 in net income (profit) each year or $0.15 on an earnings per share basis. Harvard Bioscience employs 519 workers across the globe.

What is Harvard Bioscience's official website?

The official website for Harvard Bioscience is http://www.harvardbioscience.com/.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL ROAD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected]


MarketBeat Community Rating for Harvard Bioscience (NASDAQ HBIO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  411
MarketBeat's community ratings are surveys of what our community members think about Harvard Bioscience and other stocks. Vote "Outperform" if you believe HBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/21/2019 by MarketBeat.com Staff

Featured Article: Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel